MWMarcel Wacker

Marcel Wacker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcel Wacker has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • Annika Nelde

    Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen, Tübingen, Germany

    12 shared publications
  • Hans-Georg Rammensee

    Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany

    11 shared publications
  • Helmut Rainer Salih

    Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany

    11 shared publications
  • Juliane Stickel Walz

    Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen, Tübingen, Germany

    11 shared publications
  • Yacine Maringer

    Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany

    10 shared publications
  • Jens Bauer

    Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany 2. Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Tübingen, Germany

    9 shared publications

Latest Publications

  • Open Access

    PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development

    by Steffen Lemke, Marissa L. Dubbelaar, Patrick Zimmermann, Jens Bauer, Annika Nelde, Naomi Hoenisch Gravel, Jonas Scheid, Marcel Wacker, Susanne Jung, Anna Dengler, et al.

    Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the development of personalized as well as off-the-shelf immunotherapy approaches remains challenging. Here, we introduce the open-access Peptides for Cancer Immunotherapy Database (PCI-DB, https://pci-db.org/), a comprehensive resource of immunopeptidome data originating from various malignant and benign primary tissues that provides the research community with a convenient tool to facilitate the identification of peptide targets for immunotherapy development. The PCI-DB includes > 6.6 million HLA class I and > 3.4 million HLA class II peptides from over 40 tissue types and cancer entities analyzed uniformly using high-sensitive nf-core bioinformatics pipelines and applying a global peptide false discovery rate. First application of the database provided insights into the representation of cancer-testis antigens across malignant and benign tissues, enabling the identification and characterization of cross-tumor entity and entity-specific tumor-associated antigens as well as naturally presented neoepitopes from frequent cancer mutations. Further, we used the PCI-DB to design personalized peptide vaccines for two patients suffering from metastatic cancer. In a retrospective analysis, PCI-DB enabled the composition of both a multi-peptide vaccine comprising non-mutated, highly frequent tumor-associated antigens matching the immunopeptidome of the individual patient´s tumor and a neoepitope-based vaccine matching the mutational profile of a cancer patient. Both vaccine approaches induced potent and long-lasting T-cell responses, accompanied by long-term survival of these advanced cancer patients. In conclusion, the PCI-DB provides a highly versatile tool to broaden the understanding of cancer-related antigen presentation and, ultimately, supports the development of novel immunotherapies.


  • Open Access

    MHCquant2 refines immunopeptidomics tumor antigen discovery

    by Jonas Scheid, Steffen Lemke, Naomi Hoenisch-Gravel, Anna Dengler, Timo Sachsenberg, Arthur Declerq, Ralf Gabriels, Jens Bauer, Marcel Wacker, Leon Bichmann, et al.

    The identification of human leukocyte antigen (HLA)-presented peptides as targets of anti-cancer T cell response is pivotal for the development of novel immunotherapies. Mass spectrometry (MS)-based immunopeptidomics enables the detection of these peptides, yet confident identifications and thus implementation in immunotherapy design are hampered by the high diversity and low abundance of naturally presented HLA peptides. Here, we introduce MHCquant2, a Nextflow-based open-source pipeline that leverages OpenMS tools and peptide property predictors (DeepLC, MS2PIP) for highly sensitive and scalable HLA peptide identification and quantification across various MS platforms. MHCquant2 increased peptide identifications up to 27% with a significant expansion of low-abundant peptides, outperforming state-of-the-art pipelines. Using MHCquant2 we build a comprehensive benign tissue repository comprising re-analyzed data from available benign immunopeptidomes and a novel benignMHCquant2 dataset, adding more than 160,000 novel naturally presented HLA peptides. First applications of this benign repository and the MHCquant2 pipeline enabled (i) the refinement of tumor-associated antigens, (ii) the detection of novel, high-frequent tumor-exclusive peptide antigens for multiple tumor entities, and (iii) the identification and quantification of mutation-derived low-abundant neoepitopes. MHCquant2 refines tumor antigen discovery in immunopeptidomics, paving the way for the implementation of off-the-shelf and personalized immunotherapy design.


  • Open Access

    TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

    by Naomi Hoenisch Gravel, Annika Nelde, Jens Bauer, Lena Mühlenbruch, Sarah M. Schroeder, Marian C. Neidert, Jonas Scheid, Steffen Lemke, Marissa L. Dubbelaar, Marcel Wacker, et al.

    T cell recognition of human leukocyte antigen (HLA)-presented tumor-associated peptides is central for cancer immune surveillance. Mass spectrometry (MS)-based immunopeptidomics represents the only unbiased method for the direct identification and characterization of naturally presented tumor-associated peptides, a key prerequisite for the development of T cell-based immunotherapies. This study reports on the implementation of ion mobility separation-based time-of-flight (TOFIMS) MS for next-generation immunopeptidomics, enabling high-speed and sensitive detection of HLA-presented peptides. Applying TOFIMS-based immunopeptidomics, a novel extensive benignTOFIMS dataset was generated from 94 primary benign samples of solid tissue and hematological origin, which enabled the expansion of benign reference immunopeptidome databases with > 150,000 HLA-presented peptides, the refinement of previously described tumor antigens, as well as the identification of frequently presented self antigens and not yet described tumor antigens comprising low abundant mutation-derived neoepitopes that might serve as targets for future cancer immunotherapy development.


  • Open Access

    Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

    by Jonas S. Heitmann, Claudia Tandler, Maddalena Marconato, Annika Nelde, Timorshah Habibzada, Susanne M. Rittig, Christian M. Tegeler, Yacine Maringer, Simon U. Jaeger, Monika Denk, et al.

    T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response. We here report a Phase I/II open-label trial (NCT04954469) in 54 patients with congenital or acquired B-cell deficiency receiving one subcutaneous CoVac-1 dose. Immunogenicity in terms of CoVac-1-induced T-cell responses and safety are the primary and secondary endpoints, respectively. No serious or grade 4 CoVac-1-related adverse events have been observed. Expected local granuloma formation has been observed in 94% of study subjects, whereas systemic reactogenicity has been mild or absent. SARS-CoV-2-specific T-cell responses have been induced in 86% of patients and are directed to multiple CoVac-1 peptides, not affected by any current Omicron variants and mediated by multifunctional T-helper 1 CD4+ T cells. CoVac-1-induced T-cell responses have exceeded those directed to the spike protein after mRNA-based vaccination of B-cell deficient patients and immunocompetent COVID-19 convalescents with and without seroconversion. Overall, our data show that CoVac-1 induces broad and potent T-cell responses in patients with B-cell/antibody deficiency with a favorable safety profile, which warrants advancement to pivotal Phase III safety and efficacy evaluation. ClinicalTrials.gov identifier NCT04954469.


  • Top Cited Papers
    Open Access

    Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma

    by Reza Naghavian, Wolfgang Faigle, Pietro Oldrati, Jian Wang, Nora C. Toussaint, Yuhan Qiu, Gioele Medici, Marcel Wacker, Lena K. Freudenmann, Pierre-Emmanuel Bonté, et al.

    Microbial organisms have key roles in numerous physiological processes in the human body and have recently been shown to modify the response to immune checkpoint inhibitors1,2. Here we aim to address the role of microbial organisms and their potential role in immune reactivity against glioblastoma. We demonstrate that HLA molecules of both glioblastoma tissues and tumour cell lines present bacteria-specific peptides. This finding prompted us to examine whether tumour-infiltrating lymphocytes (TILs) recognize tumour-derived bacterial peptides. Bacterial peptides eluted from HLA class II molecules are recognized by TILs, albeit very weakly. Using an unbiased antigen discovery approach to probe the specificity of a TIL CD4+ T cell clone, we show that it recognizes a broad spectrum of peptides from pathogenic bacteria, commensal gut microbiota and also glioblastoma-related tumour antigens. These peptides were also strongly stimulatory for bulk TILs and peripheral blood memory cells, which then respond to tumour-derived target peptides. Our data hint at how bacterial pathogens and bacterial gut microbiota can be involved in specific immune recognition of tumour antigens. The unbiased identification of microbial target antigens for TILs holds promise for future personalized tumour vaccination approaches.


  • Open Access

    Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

    by Tatjana Bilich, Malte Roerden, Yacine Maringer, Annika Nelde, Jonas S. Heitmann, Marissa L. Dubbelaar, Andreas Peter, Sebastian Hörber, Jens Bauer, Jonas Rieth, et al.

    Supplementary Figures S1-S5 Supplementary Tables S1-S3 revised

  • Open Access

    Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

    by Tatjana Bilich, Malte Roerden, Yacine Maringer, Annika Nelde, Jonas S. Heitmann, Marissa L. Dubbelaar, Andreas Peter, Sebastian Hörber, Jens Bauer, Jonas Rieth, et al.

    Supplementary Figures S1-S5 Supplementary Tables S1-S3 revised

  • Open Access

    Data from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

    by Tatjana Bilich, Malte Roerden, Yacine Maringer, Annika Nelde, Jonas S. Heitmann, Marissa L. Dubbelaar, Andreas Peter, Sebastian Hörber, Jens Bauer, Jonas Rieth, et al.

    Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T-cell responses in unexposed and SARS-CoV-2–infected patients with cancer to characterize SARS-CoV-2 immunity and to identify immunologic parameters contributing to COVID-19 outcome. Unexposed patients with hematologic malignancies presented with reduced prevalence of preexisting SARS-CoV-2 cross-reactive CD4+ T-cell responses and signs of T-cell exhaustion compared with patients with solid tumors and healthy volunteers. Whereas SARS-CoV-2 antibody responses did not differ between patients with COVID-19 and cancer and healthy volunteers, intensity, expandability, and diversity of SARS-CoV-2 T-cell responses were profoundly reduced in patients with cancer, and the latter associated with a severe course of COVID-19. This identifies impaired SARS-CoV-2 T-cell immunity as a potential determinant for dismal outcome of COVID-19 in patients with cancer.Significance:This first comprehensive analysis of SARS-CoV-2 immune responses in patients with cancer reports on the potential implications of impaired SARS-CoV-2 T-cell responses for understanding pathophysiology and predicting severity of COVID-19, which in turn might allow for the development of therapeutic measures and vaccines for this vulnerable patient population.See related commentary by Salomé and Horowitz, p. 1877.This article is highlighted in the In This Issue feature, p. 1861

  • Open Access

    timsTOF mass spectrometry-based immunopeptidomics refines tumor antigen identification

    by Naomi Hoenisch Gravel, Annika Nelde, Jens Bauer, Lena Mühlenbruch, Sarah Schroeder, Marian Neidert, Jonas Scheid, Steffen Lemke, Marissa Dubbelaar, Marcel Wacker, et al.

    T cell recognition of human leukocyte antigen (HLA)-presented tumor-associated peptides is central for cancer immune surveillance. Mass spectrometry (MS)-based immunopeptidomics represents the only unbiased method for the direct identification and characterization of naturally presented tumor-associated peptides, a key prerequisite for the development of T cell-based immunotherapies. This study reports on the de novo implementation of ion mobility separation-based timsTOF MS for next-generation immunopeptidomics, enabling high-speed and sensitive detection of HLA-presented peptides. A direct comparison of timsTOF-based with state-of-the-art immunopeptidomics using orbitrap technology showed significantly increased HLA peptide identifications from benign and malignant primary samples of solid tissue and hematological origin. First application of timsTOF-based immunopeptidomics for tumor antigen discovery enabled (i) the expansion of benign reference immunopeptidome databases with > 150,000 HLA-presented peptides from 94 primary benign tissue samples, (ii) the refinement of previously described tumor antigens, and (iii) the identification of a vast array of novel tumor antigens, comprising low abundant neoepitopes, that might serve as targets for future cancer immunotherapy development.

  • Open Access

    The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

    by Jens Bauer, Natalie Köhler, Yacine Maringer, Philip Bucher, Tatjana Bilich, Melissa Zwick, Severin Dicks, Annika Nelde, Marissa Dubbelaar, Jonas Scheid, et al.

    The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma. DNAJB1-PRKACA-derived HLA class I and HLA class II ligands induce multifunctional cytotoxic CD8+ and T-helper 1 CD4+ T cells, and their cellular processing and presentation in DNAJB1-PRKACA expressing tumor cells is demonstrated by mass spectrometry-based immunopeptidome analysis. Single-cell RNA sequencing further identifies multiple T cell receptors from DNAJB1-PRKACA-specific T cells. Vaccination of a fibrolamellar hepatocellular carcinoma patient, suffering from recurrent short interval disease relapses, with DNAJB1-PRKACA-derived peptides under continued Poly (ADP-ribose) polymerase inhibitor therapy induces multifunctional CD4+ T cells, with an activated T-helper 1 phenotype and high T cell receptor clonality. Vaccine-induced DNAJB1-PRKACA-specific T cell responses persist over time and, in contrast to various previous treatments, are accompanied by durable relapse free survival of the patient for more than 21 months post vaccination. Our preclinical and clinical findings identify the DNAJB1-PRKACA protein as source for immunogenic neoepitopes and corresponding T cell receptors and provide efficacy in a single-patient study of T cell-based immunotherapy specifically targeting this oncogenic fusion.